Developed by Kenvue, the new formulation arrives as patient dissatisfaction with existing non-prescription pain management reaches a reported 75%. By merging two established ingredients into a single dose, the product eliminates the need for patients to coordinate staggered dosing schedules or manage multiple medications independently. Eight clinical studies confirmed that the combination outperforms either acetaminophen or naproxen sodium when taken separately.

Dr. Rajesh Mishra, Chief Medical Officer at Kenvue, noted that the treatment is designed to break the cycle of trial-and-error often associated with persistent pain. For clinicians, the approval offers a standardized, multimodal option that remains opioid-free. The FDA has granted a three-year exclusivity period for this specific OTC formulation, which is expected to reach major U.S. retailers in the coming months. Detailed clinical data supporting the product's efficacy is scheduled for presentation at the 2026 PAINWeek conference.